87 related articles for article (PubMed ID: 24214826)
1. Cross-modulation and molecular interaction at the Cav3.3 protein between the endogenous lipids and the T-type calcium channel antagonist TTA-A2.
Cazade M; Nuss CE; Bidaud I; Renger JJ; Uebele VN; Lory P; Chemin J
Mol Pharmacol; 2014 Feb; 85(2):218-25. PubMed ID: 24214826
[TBL] [Abstract][Full Text] [Related]
2. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice.
Kraus RL; Li Y; Gregan Y; Gotter AL; Uebele VN; Fox SV; Doran SM; Barrow JC; Yang ZQ; Reger TS; Koblan KS; Renger JJ
J Pharmacol Exp Ther; 2010 Nov; 335(2):409-17. PubMed ID: 20682849
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine.
Ross HR; Gilmore AJ; Connor M
Br J Pharmacol; 2009 Mar; 156(5):740-50. PubMed ID: 19226289
[TBL] [Abstract][Full Text] [Related]
4. T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids.
Barbara G; Alloui A; Nargeot J; Lory P; Eschalier A; Bourinet E; Chemin J
J Neurosci; 2009 Oct; 29(42):13106-14. PubMed ID: 19846698
[TBL] [Abstract][Full Text] [Related]
5. CaV3.2 T-type Ca2+ channels mediate the augmented calcium influx in carotid body glomus cells by chronic intermittent hypoxia.
Makarenko VV; Ahmmed GU; Peng YJ; Khan SA; Nanduri J; Kumar GK; Fox AP; Prabhakar NR
J Neurophysiol; 2016 Jan; 115(1):345-54. PubMed ID: 26561606
[TBL] [Abstract][Full Text] [Related]
6. T-type calcium channel antagonist, TTA-A2 exhibits anti-cancer properties in 3D spheroids of A549, a lung adenocarcinoma cell line.
Kumari N; Bhargava A; Rath SN
Life Sci; 2020 Nov; 260():118291. PubMed ID: 32810510
[TBL] [Abstract][Full Text] [Related]
7. State-dependent properties of a new T-type calcium channel blocker enhance Ca(V)3.2 selectivity and support analgesic effects.
Francois A; Kerckhove N; Meleine M; Alloui A; Barrere C; Gelot A; Uebele VN; Renger JJ; Eschalier A; Ardid D; Bourinet E
Pain; 2013 Feb; 154(2):283-293. PubMed ID: 23257507
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human recombinant T-type calcium channels by N-arachidonoyl 5-HT.
Gilmore AJ; Heblinski M; Reynolds A; Kassiou M; Connor M
Br J Pharmacol; 2012 Nov; 167(5):1076-88. PubMed ID: 22624680
[TBL] [Abstract][Full Text] [Related]
9. T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats.
Uslaner JM; Smith SM; Huszar SL; Pachmerhiwala R; Hinchliffe RM; Vardigan JD; Nguyen SJ; Surles NO; Yao L; Barrow JC; Uebele VN; Renger JJ; Clark J; Hutson PH
Neuropharmacology; 2012 Mar; 62(3):1413-21. PubMed ID: 21110986
[TBL] [Abstract][Full Text] [Related]
10. Biophysical and pharmacological characterization of spermatogenic T-type calcium current in mice lacking the CaV3.1 (alpha1G) calcium channel: CaV3.2 (alpha1H) is the main functional calcium channel in wild-type spermatogenic cells.
Stamboulian S; Kim D; Shin HS; Ronjat M; De Waard M; Arnoult C
J Cell Physiol; 2004 Jul; 200(1):116-24. PubMed ID: 15137064
[TBL] [Abstract][Full Text] [Related]
11. Positive allosteric interaction of structurally diverse T-type calcium channel antagonists.
Uebele VN; Nuss CE; Fox SV; Garson SL; Cristescu R; Doran SM; Kraus RL; Santarelli VP; Li Y; Barrow JC; Yang ZQ; Schlegel KA; Rittle KE; Reger TS; Bednar RA; Lemaire W; Mullen FA; Ballard JE; Tang C; Dai G; McManus OB; Koblan KS; Renger JJ
Cell Biochem Biophys; 2009; 55(2):81-93. PubMed ID: 19582593
[TBL] [Abstract][Full Text] [Related]
12. Modulation of T-type calcium channels by bioactive lipids.
Chemin J; Cazade M; Lory P
Pflugers Arch; 2014 Apr; 466(4):689-700. PubMed ID: 24531745
[TBL] [Abstract][Full Text] [Related]
13. The endocannabinoid N-arachidonoyl dopamine (NADA) selectively induces oxidative stress-mediated cell death in hepatic stellate cells but not in hepatocytes.
Wojtalla A; Herweck F; Granzow M; Klein S; Trebicka J; Huss S; Lerner R; Lutz B; Schildberg FA; Knolle PA; Sauerbruch T; Singer MV; Zimmer A; Siegmund SV
Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G873-87. PubMed ID: 22301114
[TBL] [Abstract][Full Text] [Related]
14. Chemical determinants involved in anandamide-induced inhibition of T-type calcium channels.
Chemin J; Nargeot J; Lory P
J Biol Chem; 2007 Jan; 282(4):2314-23. PubMed ID: 17121818
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of store-operated calcium channels by N-arachidonoyl glycine (NAGly): no evidence for the involvement of lipid-sensing G protein coupled receptors.
Deveci A; Hasna J; Bouron A
Sci Rep; 2020 Feb; 10(1):2649. PubMed ID: 32060392
[TBL] [Abstract][Full Text] [Related]
16. Contrasting the effects of nifedipine on subtypes of endogenous and recombinant T-type Ca2+ channels.
Shcheglovitov A; Zhelay T; Vitko Y; Osipenko V; Perez-Reyes E; Kostyuk P; Shuba Y
Biochem Pharmacol; 2005 Mar; 69(5):841-54. PubMed ID: 15710361
[TBL] [Abstract][Full Text] [Related]
17. The Cav3.2/alpha1H T-type Ca2+ current is a molecular determinant of excitatory effects of GABA in adult sensory neurons.
Aptel H; Hilaire C; Pieraut S; Boukhaddaoui H; Mallié S; Valmier J; Scamps F
Mol Cell Neurosci; 2007 Oct; 36(2):293-303. PubMed ID: 17716912
[TBL] [Abstract][Full Text] [Related]
18. Block of human CaV3 channels by the diuretic amiloride.
Lopez-Charcas O; Rivera M; Gomora JC
Mol Pharmacol; 2012 Oct; 82(4):658-67. PubMed ID: 22767612
[TBL] [Abstract][Full Text] [Related]
19. Ca(v)3.2 channel is a molecular substrate for inhibition of T-type calcium currents in rat sensory neurons by nitrous oxide.
Todorovic SM; Jevtovic-Todorovic V; Mennerick S; Perez-Reyes E; Zorumski CF
Mol Pharmacol; 2001 Sep; 60(3):603-10. PubMed ID: 11502893
[TBL] [Abstract][Full Text] [Related]
20. Chelating luminal zinc mimics hydrogen sulfide-evoked colonic pain in mice: possible involvement of T-type calcium channels.
Matsunami M; Kirishi S; Okui T; Kawabata A
Neuroscience; 2011 May; 181():257-64. PubMed ID: 21354272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
